Unmutated but T cell dependent IgM antibodies targeting Streptococcus suis play an essential role in bacterial clearance

PLoS Pathog. 2024 Jan 19;20(1):e1011957. doi: 10.1371/journal.ppat.1011957. eCollection 2024 Jan.

Abstract

Streptococcus suis serotype 2 is an important encapsulated bacterial swine pathogen and zoonotic agent for which no effective vaccine exists. The interaction with B cells and the humoral response against S. suis are poorly understood despite their likely relevance for a potential vaccine. We evaluated germinal center (GC) B cell kinetics, as well as the production and role of S. suis-specific antibodies following infections in a mouse model. We found that mice infected with S. suis developed GC that peaked 13-21 days post-infection. GC further increased and persisted upon periodic reinfection that mimics real life conditions in swine farms. Anti-S. suis IgM and several IgG subclasses were produced, but antibodies against the S. suis capsular polysaccharide (CPS) were largely IgM. Interestingly, depletion of total IgG from the wild-type mice sera had no effect on bacterial killing by opsonophagocytosis in vitro. Somatic hypermutation and isotype switching were dispensable for controlling the infection or anti-CPS IgM production. However, T cell-deficient (Tcrb-/-) mice were unable to control bacteremia, produce optimal anti-CPS IgM titers, or elicit antibodies with opsonophagocytic activity. SAP deficiency, which prevents GC formation but not extrafollicular B cell responses, ablated anti S. suis-IgG production but maintained IgM production and eliminated the infection. In contrast, B cell deficient mice were unable to control bacteremia. Collectively, our results indicate that the antibody response plays a large role in immunity against S. suis, with GC-independent but T cell-dependent germline IgM being the major effective antibody specificities. Our results further highlight the importance IgM, and potentially anti-CPS antibodies, in clearing S. suis infections and provide insight for future development of S. suis vaccines.

MeSH terms

  • Animals
  • Antibodies, Bacterial
  • Bacteremia*
  • Immunoglobulin G
  • Immunoglobulin M
  • Mice
  • Streptococcal Infections* / microbiology
  • Streptococcus suis* / genetics
  • Swine
  • T-Lymphocytes
  • Vaccines*

Substances

  • Antibodies, Bacterial
  • Immunoglobulin G
  • Immunoglobulin M
  • Vaccines

Grants and funding

This work was mainly supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) project grant to M.S. (no. 342150). Additional support was provided by the International Development Research Centre (IDRC) grant to MS (no. 109047) and Canadian Institutes of Health Research project grant to JDN (PJ-166028). D.D. is also the recipient of a Fonds de Recherche du Québec–Nature et Technologies (FRQ-NT) Doctoral Research Scholarship (# 268339) and the recipient of a Swine and Poultry Infectious Disease Research Center (CRIPA) scholarship supported by the FRQ-NT (# RS-170946). J.D.N. was supported by a merit scholarship from Fonds de recherche en Santé de Québec (FRQ-S). M.S. is a holder of a Canada Research Chair – Tier 1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.